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Peripheral nerve injuries are a frequent and disabling condition, which aﬀects 13 to 23 per 100.000 persons each year. Severe cases,
with structural disruption of the nerve, are associated with poor functional recovery. The experimental treatment using nerve grafts
to replace damaged or shortened axons is limited by technical diﬃculties, invasiveness, and mediocre results. Other therapeutic
choices include the adjunctive application of cultured Schwann cells and nerve conduits to guide axonal growth. The bone marrow
is a rich source of mesenchymal cells, which can be diﬀerentiated in vitro into Schwann cells and subsequently engrafted into
the damaged nerve. Alternatively, undiﬀerentiated bone marrow mesenchymal cells can be associated with nerve conduits and
afterward transplanted. Experimental studies provide evidence of functional, histological, and electromyographical improvement
following transplantation of bone-marrow-derived cells in animal models of peripheral nerve injury. This paper focuses on this
new therapeutic approach highlighting its direct translational and clinical utility in promoting regeneration of not only acute but
perhaps also chronic cases of peripheral nerve damage.

1. Introduction
The incidence of peripheral nerve injury in developed
countries is estimated between 13 and 23 per 100.000 persons
per year [1–3]. Common reported causes include motor
vehicle accidents, lacerations with blades, glass or long bone
fractures, and sports injuries. These statistics may be underestimated since only traumatic injuries that reach the health
care system are included. Nontraumatic injuries, nerve
damage secondary to abdominal or pelvic surgeries, and
lesions that are not treated at a health facility remain to be
accounted [3]. As an example, erectile dysfunction secondary
to prostate surgeries associated with iatrogenic transection of
erectile nerves occurs in approximately 35 to 86% of radical
prostatectomy surgeries [4, 5]. It is, however, in the war
scenario where the problem is more frequent. Blast injuries

predominate, often associated with complex soft tissue and
arterial wounds, most of which requiring limb amputation
[6].
Peripheral nerve injuries are classified according to their
severity, from type I, limited to demyelination, through type
V, which comprises disruption of all three layers of the nerve
endoneurium, perineurium, and epineurium. A sixth type
of injury has also been described, with diﬀerent degrees of
lesion within individual fascicules from the same nerve [6].
Recovery is inversely proportional to the severity of damage.
Endogenous repair initiates after injury but usually does not
sustain itself beyond 12 months [7]. If the nerve does not
heal within this period of time, recovery is unlikely and
chronic pain and disability may persist. In serious injuries,
surgical intervention is usually necessary, aiming to align the
damaged axonal stumps, either through end-to-end sutures
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or by interposition of a nerve graft or even a scaﬀold for
axonal growth. Frequently, however, the procedure does not
suﬃce, and functional recovery is suboptimal [2, 6, 7].
Nerve repair is often disappointing and, despite best
eﬀorts, full functional recovery is seldom achieved, especially
regarding motor nerves [2]. The high incidence of peripheral
nerve damage, associated with poor reparative outcomes,
indicates the importance of the problem and the demand
for better regenerative therapies. In this context, the development of new approaches, including cell-based therapies, may
improve outcomes and diminish the resulting disability of
aﬀected victims. Indeed, preclinical ongoing studies already
show positive results in models of erectile, facial, optic, and
sciatic nerve injuries [5, 8–11].

2. The Healing Process That Follows
Nerve Injury
Peripheral nerve injury is followed by responses both from
segments of the axon, proximal, and distal to the damaged
area, and from the surrounding neural and nonneural cells.
As a first endogenous reparative attempt, the neuronal cell
body increases in size, the Nissl bodies dissolve, and the
nucleus migrates peripherally, initiating a process of protein
synthesis [12]. The distal detached nerve undergoes intrinsic
fragmentation, as the first stage of Wallerian degeneration.
Interestingly, distal nerve disintegration does not start immediately upon injury. In primates, axons remain intact during
days and can still transmit electric potentials when stimulated [13, 14]. The following fragmentation of the axon is a
rapid event and seems to be mediated by activated intrinsic
proteases, including calpain and the ubiquitin-protease
system, and once started, it is completed within hours [15–
17]. Axonal and myelin debris is later phagocytosed by
local Schwann cells and recruited macrophages [18]. These
latter cells opportunely infiltrate through the broken bloodnerve-barrier and myelin sheathing, attracted by specific
chemokines and cytokines [12, 19]. Neutralization of these
factors by specific antibodies delays demyelination and, in
consequence, axonal regeneration [12]. In fact, clearance
of myelin debris seems to be an important step for repair
since myelin contains inhibitors of axonal growth and may,
therefore, impair regeneration [20].
Schwann cells have a central role in nerve repair, not
only concerning Wallerian degeneration and remyelination
but also in promoting axonal growth. Experiments in which
these cells were either decreased in number or made nonfunctional indicate a deficient axonal regeneration, placing
the Schwann cell as an integral component of the regenerative process [21]. After injury, the Schwann cells become
activated, assume a more primitive phenotype, and stimulate
axonal growth, with upregulation of growth-related genes,
including those that encode intrinsic neurotrophic factors
and key transcription factors [2, 8, 22]. Activated Schwann
cells produce collagen and laminin, creating a tunnel of
extracellular matrix, and express cell adhesion molecules and
receptors, including IL-1, N-cadherin, gamma integrins, and
the neural cell adhesion molecule (N-CAM) [2].
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The mechanisms through which Schwann cells and the
damaged axons communicate are poorly understood. Vrbova
et al. suggested that an interaction between neurotransmitters and their upregulated receptors may be involved
and demonstrated that drugs that inhibit the binding of
acetylcholine to its receptors and the binding of ATP to P2Y
receptors decrease axonal regeneration [23]. Additionally,
HNK-1 glycan, which is a marker of regeneration mediated
by Schwann cells in motor nerves, was decreased in the
animals with neurotransmitter blockage [23, 24]. Goethals
et al. describe Toll-like receptors as mediators of damage
recognition between Schwann cells and axons [25]. Schwann
cells constitutively express Toll-like receptors and, therefore,
play a sentinel role. Toll-like receptor ligands released by
degenerating axons stimulate Schwann and immune cells to
clear myelin and start the reparative process.
The resulting supportive environment yields Schwann
cell proliferation, formation of Büngner bands, and, finally,
axonal sprouting [2, 26, 27]. This sprouting occurs at a
rate of 1 to 4 mm per day, with progressive myelination
of the fibers by the neighboring Schwann cells. The final
repaired nerve usually presents thinner myelin sheets with
shorter nodal lengths, less functional than the original nerve
[28]. Time is an important factor aﬀecting nerve repair. The
supportive response mediated by neural and nonneural cells
is more pronounced in the few months that follow nerve
injury [6, 7, 28, 29]. When surgical intervention is delayed,
the chronically denervated Schwann cells begin spontaneous
apoptosis and repair becomes less probable. Recently, Gordon et al. demonstrated that although denervation of the
distal stump is the main determinant, the denervated muscle
also negatively impacts functional outcome [29]. Therefore,
attempts to enhance nerve regeneration should be initiated
as early as possible.

3. Interventions to Improve
Peripheral Nerve Repair
Nerve repair requires a complex interaction of a scaﬀold for
axonal proliferation, supportive cells such as the Schwann
cells, growth factors, and extracellular matrix [2, 30]. Therefore, alignment of the nerve stumps stands as one of the first
interventions after peripheral nerve injury. When end-toend suture of the nerve is not possible, the interposition of
a nerve conduit becomes necessary. Autologous grafts are
often harvested from the sural or sensory nerves; however,
sometimes there are limitations such as tissue availability, size incompatibilities, and deformities. Nevertheless,
autologous nerve grafts are considered the gold standard
for repairing peripheral nerve gaps [31]. Less frequently,
allografts can be used, with the disadvantages of requiring
immunosuppression and of producing worse outcomes than
autografts.
More recently, tissue engineering has provided nerve
conduits, which function as guides for axonal growth.
Depending on the materials used for their construction, they
can be classified as natural, when based on laminin, collagen
or even vessels and decellularized nerves, or artificial, usually
made of polymers. Artificial, nonbiodegradable scaﬀolds
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aid nerve growth and provide beneficial results. However,
these conduits may lead to chronic inflammation and tissue
compression and therefore must be surgically removed once
neural healing has been concluded. To avoid the hurdles of
a second surgery on the injury site, biodegradable scaﬀolds
are preferred. Table 1 includes some examples of experimental studies that used biodegradable scaﬀolds. Concerning
humans, recently Åberg et al. suggested that wrappingaround injured wrist/forearm nerves with a resorbable
poly[(R)-3-hydroxybutyrate] (PHB) implant, promoted significant sensory and motor improvements when compared
to end-to-end epineural suture alone [32]. Importantly, no
adverse eﬀects were associated with the procedure, therefore
considered safe.
Sensory nerves usually have better outcomes than motor
nerves, after reconstructive interventions [48]. However,
sensory repair is only warranted in areas of critical sensation,
while motor nerves are usually indispensable. Motor nerve
repair is mostly worth when the site of injury is close to the
end organ because if the length to be repaired is too long,
by the time reinnervation is achieved, the end-organ may
be already unresponsive. In these cases, nerve transfer procedures, if available, may be attractive alternatives.
The major limitation for use of nerve conduits is the
low rate of axonal growth, which may not yield full repair
within the available time. Studies have shown that the
conduits are eﬀective in promoting repair of nerve gaps
measuring up to 3 cm, while nerve autografts are required
for bridging of larger distances [49, 50]. As an attempt to
apply nerve guides for axonal growth in larger nerve injuries,
Kokai et al. used polymer tube-like scaﬀolds associated with
microparticles of GDNF, aiming to increase the rate of axonal
growth and improve the success of functional restoration
[40]. Endogenous Schwann cells have been shown to be
attracted by the GDNF particles, increasing the rate of nerve
regeneration. Similarly, Liu et al. observed higher nerve
repair rates in rats with peripheral nerve injury treated with
biodegradable conduits associated with nerve growth factor
(NGF) [51].
Schwann cells are also potentiated by associations with
other cell types or by bioengineering. Olfactory ensheathing
cells (OECs) successfully repair peripheral nerve injuries and
with less eﬃciency central nervous system axonal lesions
[52]. However, Verdú et al. and You et al. demonstrated
that the association of Schwann cells and OECs promotes
better myelination and functional repair to injured sciatic
axons than either cell type alone [53, 54]. Another studied approach involves genetic engineering, inducing the
Schwann cells to express cell adhesion molecules, therefore
improving their regenerative capacity. Increasing the rate
of axonal repair may enhance the chances of successful
functional recovery since the outcomes are in most cases
time dependent. Lavdas et al. have investigated the eﬀects
of Schwann cells genetically modified to overexpress cell
adhesion molecules, mostly the polysialylated form of neural
cell adhesion molecule NCAM, on nervous system repair [55,
56]. It is hypothesized that these adhesion molecules improve
transplanted cell migration, increasing their interaction with
the host environment, therefore promoting more eﬃcient
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functional integration. Additionally, cell adhesion molecules
also stimulate axonal growth and remyelination, increasing
the rate of renervation [57, 58].

4. Sources of Schwann Cells and
Experimental Studies
Schwann cells are embryologically derived from the neural
crest [59, 60]. Some neural crest pluripotent and stem cells
(NCSCs) persist in adult specimens in sites of gliogenesis
such as the sciatic nerve and dorsal root ganglia. Migration,
proliferation, expression of growth factors, and remyelination capacity are listed features associated with Schwann
cells, indicating their stem cell behavior [61, 62]. Attempts
to use Schwann cells expanded in culture for neural repair
have been described in the literature for over two decades
[62]. Recently, Hood et al. used artificial tubes filled with
autologous Schwann cells to replace gaps between sciatic
nerve stumps of rats, with reported functional recovery
[63].
The combination of axonal scaﬀolds and transplanted
Schwann cells provides adequate support for peripheral
nerve repair and has been investigated in the experimental
setting as a strategy to circumvent the limitations of surgical
repair [34, 37, 45]. The cells can be delivered inside a hollow
tube, seeded in a hydrogel and subsequently filled into the
lumen of the conduit, or placed inside a conduit containing
a supportive structure [30]. Most studies use the first type
of delivery, but it may be associated with substantial cell
loss [38, 43, 46, 63]. Improved outcomes have been obtained
using the second [34, 37] and third [45] approaches, but
these are more technically complicated and costly. Although
successful, these procedures are limited by the high number
of cells required for each intervention, potential injury to the
donor nerve, and fibroblast contamination of the cultures
[64]. Therefore, alternative sources of supportive cells have
been researched.
The bone marrow may be an attractive source despite
the large number of available tissues from which Schwann
cells can be obtained. Bone marrow mesenchymal cells have
been studied for years in the context of in vitro expansion
and transplantation [65]. Their ease of access, abundance,
and safety are important attributes, especially concerning
clinical application. Mesenchymal stromal cells (MSCs) or
bone marrow stromal cells are multipotent somatic stem
cells, from a nonhematopoietic precursor anchored in bone
marrow that can diﬀerentiate in mesodermal cell linages,
neural phenotypes, and also into Schwann-like cells [47,
66]. When MSCs are placed in an appropriate culture
media, they transdiﬀerentiate into a glial cell phenotype
that expresses S100, GFAP, and p75 [67, 68]. In vitro
diﬀerentiated cells show promising results when associated
with artificial conduits and acellular grafts, promoting axonal
and functional recovery [39, 41, 67].
Table 1 describes several preclinical studies that evaluate
the reparative eﬀects of diﬀerent kinds of cell therapy upon
peripheral nerve damage. Besides nervous tissue and bone
marrow, other alternative sources of cell are investigated,
such as the adipose tissue and skin. The skin dermis is
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Table 1: Preclinical studies evaluating cell therapy for peripheral nerve repair∗ .
Study
McKenzie et al. [33]

Injury type/animal model
Sciatic nerve crush injury
in myelin-deficient mice

Cellular type/factor
Skin-derived precursors diﬀerentiated
into Schwann cells

Major findings
Remyelination and functional
recovery

Udina et al. [34]

Sciatic nerve injury in mice
(0.6 cm gap)

Collagen guides seeded with allogeneic
Schwann cells plus FK-506

Successful regeneration and
functional recovery

Negishi et al. [11]

Optic nerve injury in rats
(transection)

Extracellular matrix Schwann cells and
neurotrophins

Axonal regeneration of retinal
ganglion cells

Reid et al. [35]

Sciatic nerve injury in rats
(1.0 cm gap)

Adipose-derived stem cells

Dorsal root ganglia protection
from apoptosis

di Summa et al. [36]

Sciatic nerve injury in rats
(1.0 cm gap)

Nerve fibrin conduits seeded with
adipose-derived stem cells

Enhanced peripheral nerve repair

Evans et al. [37]

Sciatic nerve injury in rats
(1.2 cm gap)

Biosynthetic conduits seeded with
Schwann cells

Increased nerve regeneration

Koshimune et al. [38]

Sciatic nerve injury in rats
(1.2 cm gap)

Bioabsorbable Schwann cell-coated
conduits

Axonal regeneration

Ladak et al. [39]

Sciatic nerve injury in rats
(1.2 cm gap)

Bone marrow MSCs diﬀerentiated into
Schwann-like cells seeded in collagen
conduits

Regeneration of sciatic
motoneuron

Kokai et al. [40]

Sciatic nerve injury in rats
(1.5 cm gap)

Scaﬀolds containing GDNF
microparticles

Increased rate of nerve
regeneration; migration and
proliferation of Schwann cells

Dezawa et al. [41]

Sciatic nerve injury in rats
(1.5 cm gap)

Bone marrow MSCs diﬀerentiated into
Schwann-like cells suspended in Matrigel
injected into hollow fibers

Successful nerve regeneration
and myelination

Marchesi et al. [42]

Sciatic nerve injury in rats
(1.6 cm gap)

Guides filled with skin-derived stem cells

Functional recovery and
myelination

Ansselin et al. [43]

Sciatic nerve injury in rats
(1.8 cm gap)

Nerve guides filled with syngeneic
Schwann cells

Successful nerve regeneration
conditional to number of cells
implanted

May et al. [5]

Cavernous nerves sections
in rats (0.5 cm gap)

Silicon tubes seeded with
GDNF-transduced Schwann cells

Increased recovery of erectile
function

Sun et al. [44]

Facial nerve injury in rats
(0.8 cm gap)

Decellularized artery allografts with
autologous adipose-derived stem cells

Nerve repair and functional
recovery

Wang et al. [10]

Facial nerve injury in
rabbits (1.0 cm gap)

Autologous vein graft filled with
autologous MSCs diﬀerentiated into
Schwann cells

Improvement of functional
recovery and upregulated myelin
mRNA

Cheng and Chen [45]

Sciatic nerve injury in
rabbits (2.0 cm gap)

Polyglactin scaﬀolds seeded with
Schwann cells and coated with
biomembranes

Successful nerve regeneration

Zhang et al. [46]

Tibial nerve injury in
rabbits (4.0 cm gap)

Autogenous venous graft filled with
Schwann cells

Successful nerve regeneration
and electromyographic
improvement
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Table 1: Continued.

Study
Wakao et al. [47]

Hu et al. [31]

Injury type/animal model
Non-human primates
median nerve injury
(2.0 cm gap)
Non-human primates ulnar
nerve injury (4.0 cm gap)

Cellular type/factor

Major findings

Collagen guides seeded with bone
marrow MSC-derived Schwann cells

Functional, histological, and
electromyographical recovery

Acellular allogeneic nerve grafts with
autologous MSCs

Structural and functional
peripheral nerve repair

∗

The studies are grouped by animal model, nerve type, and injury size, starting with mice, followed by rats, rabbits, and nonhuman primates. The table does
not list all the available studies but describes the main publications.

another investigated cell source and contains neural crestrelated precursors skin precursor cells SKPCs that can differentiate into neural crest cell types in vitro, including those
with characteristics of peripheral neurons and Schwann cells
[33, 69]. Also, the bulge area of the hair and whisker follicles
harbors NCSC that can diﬀerentiate into Schwann-like
cells, becoming an accessible source of cells for transplant.
Both NCSC and SKPC have been used in experiments of
peripheral nerve and spinal cord injuries with functional
improvement after transplantation [33, 42, 70, 71].
Regarding the adipose tissue, Reid et al. showed that
diﬀerentiated adipose-derived Schwann cells expressed a
range of intrinsic neurotrophic factors [35, 72]. They also
demonstrated that the incorporation of either adipocytederived or nerve-derived Schwann cells into the repair site
significantly increased the expression of anti-apoptotic mRNA of Bcl-2 and decreased proapoptotic m-RNA Bax and
caspase-3 in dorsal root ganglia, therefore promoting a
neuroprotective eﬀect [72]. In a comparative study for sciatic
nerve repair using a fibrin conduit seeded with diﬀerent cell
populations, primary Schwann cells showed better results
over adipose and bone-marrow-derived mesenchymal stem
cells; however, the two last cell types still showed better
axonal regeneration than the control, nontreated group [36].
Adipose-tissue-derived Schwann cells have also been used in
experimental models of facial palsy with positive results [44].
Sun et al. published a study in rats with lesions of facial nerve
that presented functional and electrophysiological recovery
of nerve injuries measuring 0.8 cm.
Neural stem cells directly transplanted in the site of
peripheral nerve injury diﬀerentiate into Schwann-like cells,
secrete neural growth factors, and improve nerve regeneration [8]. In addition, these cells can enhance compatibility
between transplanted and surrounding tissue, decreasing
the necessity of immunosuppressive agents. Moreover, the
coculture and cotransplantation of neural stem cells with
Schwann cells increase the diﬀerentiation of neural stem cells
into neurons and improve functional recovery in models of
spinal cord injury [73].
Recently, Wakao et al. used collagen nerve conduits filled
with autologous bone marrow MSC diﬀerentiated in vitro
into Schwann cells to promote repair of median nerve
injuries in monkeys [47] (Table 1). Successful outcomes were
reported, with functional, histological, and electromyographical improvements. Interestingly, Hu et al. demonstrated that allogeneic acellular nerves filled with autologous, but nondiﬀerentiated, bone-marrow-derived MSC also

promoted functional recovery when placed in ulnar nerve
gaps of nonhuman primates [31]. The success rates were
comparable to those from nerve autografts and autologous
Schwann-cell-filled acellular nerves and better than controls,
which received the acellular nerves not filled with cells.
The similar outcomes of both studies raise the hypothesis
that prediﬀerentiation of MSC into Schwann cells may
not be necessary to achieve repair. Moreover, a previous
study had demonstrated that allogeneic Schwann cells locally
transplanted into a rat model of spinal cord injury induced
the infiltration of endogenous Schwann cells into the
damaged site [74]. Although the observation should not be
transposed to peripheral nerve injury, it suggests a paracrine,
rather than replacement therapeutic eﬀect. On the other
hand, Sun et al. recently published a study in rats with
facial nerve injuries treated with decellularized allogeneic
arteries filled with adipose-tissue-derived Schwann cells,
where transplanted cells survived in the graft over 8 weeks
[75]. Studies establishing the exact fate of labeled Schwann
cells are still needed. Although in vitro studies demonstrate
diﬀerentiation of the MSC into diﬀerent cell types, mainly of
mesodermal lineage, in vivo studies fail to show convincing
evidence of such event. It is possible that the MSCs promote
healing eﬀects mostly through paracrine action, inducing
recruitment of neighboring host cells, modulation of local
and perhaps systemic immune response, and improving cell
survival, than through direct cell diﬀerentiation.

5. Clinical Trial of Nerve Grafts and Scaffolds
Clinical applications of cell therapy for peripheral nerve
repair are rare. A clinical trial conducted by the University
of Stanford used scaﬀolding tubes filled with longitudinal
collagen fibers as guides for axonal growth [76]. Such tubes
were occupied by autologous cultured Schwann cells and
served as a replacement for nerve autografts, aiming to
repair short and long gaps. Results were partially reported,
including cell harvesting, expansion in culture, and assembly
of cells and nerve conduits, but clinical outcomes have not
yet been published [76]. Another proposed study (ClinicalTrials.gov identifier: NCT00953277), currently recruiting
patients, intends to evaluate the eﬀects of a commercial
nerve scaﬀold on erectile function and continence after video
laparoscopic radical prostate excision [77]. The surgery is
associated with high incidence of erectile nerve transection
and directly aﬀects postoperative quality of life of the patients
[4, 5]. According to advertisements, the product is derived

6
from human decellularized nerves and may stand as an
“oﬀ the shelf ” product, viable for three years in frozen
storage [78]. The same company sponsors a comparative
study between the above-mentioned commercial humanderived nerve scaﬀold and synthetic or biosynthetic hollow
tubes to repair peripheral nerve gaps in the hand (ClinicalTrials.gov identifier: NCT00948025) [79]. Although not yet
approached by these last two studies, cell application to the
nerve conduits may be attempted in the future.

6. Practical Issues
Cell-based therapy associated with scaﬀolds is a promising
branch of regenerative medicine. Nerve injuries are a frequent and disabling condition, usually aﬀecting young and
productive subjects, which may benefit from such procedures. The idea of using nerve conduits filled with bonemarrow mesenchymal cells may be an attractive alternative
to more aggressive therapies. If successful, the treatment
may lead to functional improvement, avoiding the hurdles
of additional surgeries and use of immunosuppressive drugs.
A hypothetical scenario would be a patient with a traumatic
limb injury, including extensive and severe damage of a
motor nerve, resulting in acute disability. There would be a
nerve gap, precluding any attempt of direct nerve suture. The
use of a nerve conduit filled with allogeneic bone marrowderived MSCs would be proposed, as an alternative to the
standard autologous nerve graft implant. The acute nature
of the condition would require a readily available source
of cells, and since MSCs are immunoprivileged, indicating
poor alloimmune response and therefore delayed rejection,
allogeneic sources would be ideal. The cells would be already
isolated from donated bone marrow, expanded in culture
without further manipulation, tested for safety and quality,
cryopreserved and ready for clinical use. The necessary
amount of cells would then be thawed and inserted into
biodegradable nerve conduits, readily implanted between
nerve stumps during microsurgery. The therapy would
require no immunosuppression and sequential functional
and electromyographical evaluations would determine the
outcomes. Expected results would be axonal repair, remyelination, and progressive functional improvement, either
through diﬀerentiation of the transplanted into Schwannlike cells or, most probably, through paracrine eﬀects of
the bone-marrow-derived MSCs on the proximal axonal
stump and remaining endogenous Schwann cells, stimulating regeneration (see Figure 1).
Cell banking is a developing resource for repair in
degenerative, inflammatory, and traumatic disorders. The
rising number of cell banking companies reflects the increasing number of emergent therapeutic applications for cells
derived from the bone marrow, cord blood, and multiple other tissues. Although the regenerative potential and
the properties of the cells change slightly from tissue to
tissue, the bone marrow still stands as a preferred source
of hematopoietic and mesenchymal cells, due safety, easy
harvesting, and previous clinical experience [65]. Allogeneic
cell banking seems more logical as an “oﬀ the shelf ” product,
however investments in autologous cell preservation may
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be also interesting, as an insurance against future illnesses.
Transplanted autologous MSCs may persist in the injury
site longer because of absent immune rejection, therefore
promoting long-lasting eﬀects.
The application of MSCs is associated with some hurdles.
The most obvious is cell viability after thawing and insertion
into the conduit. Orthopedic reconstructive surgeries are
often long-lasting and the exposure of the cells to a hostile
environment may jeopardize their survival. Therefore, one
approach would be to leave cell implantation as a final
step of the surgery, immediately followed by closure of the
incision. Perhaps, performance of the surgery by a skilled
surgeon may be critical. Additional aggressions to the cells
would be the presence of infection or any situation leading
to an acidic or hypooxygenated environment. Therefore,
these conditions must be strictly controlled before cell
transplantation. A second concern is that MSCs may lead
to abnormal, nonlinear nerve growth, due to aberrant
stimulation of the sprouting axonal buds. Although the
problem has been observed in nerves stimulated with growth
factors [80], such behavior is not expected following MSC
grafts. This potential problem may be prevented through
use of good quality conduits, possibly containing an internal
supportive structure, aiming to guide newly formed axons in
the direction of the distal nerve stump. Third, the therapy
may promote cell diﬀerentiation toward a nonexpected cell
type. Malignancy is not reported as a usual consequence
of MSC administrations, but it is possible that due to the
local host conditions the cells diﬀerentiate into nonneural
cell types. Another concern that may be discussed is the
functional integration of the transplanted cells into the
injured nerve [81], although repair of peripheral nerve is
usually more successful than central nervous system injuries.
Finally, some donor conditions may interfere with MSC
cultures, such as advanced age, smoking, and diabetes [82,
83]. In these cases, autologous use may not be the best choice.
In summary, despite the reported therapeutic benefits of
MSC therapy in experimental models of peripheral nerve
injury, there remain translational hurdles that still need to
be addressed before the realization of large clinical trials
for this treatment. In the future, this form of cell therapy
may aggregate more complex features, such as addition of
trophic factors within the conduits, manipulation of the
cells for expression of neurotrophic factors or even adhesion
molecules. On the other hand, the procedure may remain
simple and enable the investigation of therapeutic pathways,
perhaps unveiling a specific substance that would be therapeutically active, therefore sparing the use of cells.

7. Conclusions
Spontaneous peripheral nerve repair is disappointing even
after microsurgical intervention, especially concerning severe
injuries. Resulting chronic pain and disability aﬀects victims
of all ages, including those in economically active phase
of life [3]. The available treatment using nerve grafts is
very limited and invasive, and new therapeutic options are
required. Schwann cell cultures have demonstrated favorable
results in the experimental setting; however, the ideal source
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Scaﬀolding
Scaﬀolding
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Neurotrophic
factors
Endogenous
Schwann cell

(a)

Neurotrophic
factors
Endogenous
Schwann cell
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Figure 1: Stem cell with scaﬀold support in peripheral nerve injury. (a) Nerve injury with stem cell transplantation shows limited
remyelination and axonal growth between the proximal and distal stumps. (b) Nerve injury with scaﬀolding devices can be fabricated to
secrete neurotrophic factors aiming to enhance the regenerative process, but still the outcome results in limited remyelination and axonal
growth between the proximal and distal stumps. (c) The combined use of stem cells and scaﬀolding promotes best results, allowing an
improved substrate for cell-to-cell contact and increased concentrations of released neurotrophic factors. Additionally, transplanted stem
cells may stimulate endogenous Schwann cells to proliferate at a higher rate, thus enhancing remyelination and axonal growth following
peripheral nerve damage.

of cells has not yet been established. Bone-marrow-derived
mesenchymal cells present encouraging results and may
become the ideal cell for clinical translation. These cells have
been exhaustively investigated during the last two decades
and approved for use in numerous clinical trials, especially
aiming at immunomodulation and tissue repair [84].
The bulk of preclinical studies oﬀer many advantages of
MSC therapy for peripheral nerve injury. The first advantage
of bone-marrow-derived MSC is the uncomplicated and
minimally invasive harvesting of the cells through aspiration
of reduced volume of bone marrow from the iliac crest.
Second, in vitro cultures are in most cases simple, with
adequate proliferation rates and high cell viability [65, 66].
Large number of cells can be obtained within a few weeks.
Third, these cells are considered safe, and not associated with
malignancy, uncontrolled proliferation or graft-versus-host
disease. Fourth, MSCs are immunologically privileged and,
thus, even allogeneic cells are not readily rejected by the host.
Although some immune response is elicited through time,
the cells survive long enough for therapeutic eﬀectiveness
without need of immunosuppressant drugs [84]. Fifth,
in vitro diﬀerentiation into Schwann cells is possible and
already described by several authors [30, 37, 63]. Finally,

MSCs secrete trophic factors, stimulating neuron regeneration, and, possibly, contributing to a supportive environment
[85].
Cultured cells, combined with adjunctive treatments
such as axonal growth guides, may be a feasible approach
for future clinical studies (see Figure 1). Severe injuries in
which nerve grafts are not available may benefit from this
strategy that may provide an extracellular substrate for the
transplanted cells and spared host cells allowing a bridge
for cellular integration and/or a cellular and molecular
pathway for improved paracrine eﬀects. Moreover, studies
investigating the eﬀects of these cells over situations of
delayed surgical intervention and chronic axonal denervation
have not been reported. The neurotropic eﬀect of these
cells, combined with a favorable eﬀect over the surrounding
environment, may prolong the time window for axonal
regeneration and, perhaps, improve the rates of functional
restoration even in chronic cases.
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